Ciphergen Biosystems, Inc.

Agreement signed to evaluate proteomic system for ovarian cancer diagnostics

Published in Physician Law Weekly, May 25th, 2005

Ciphergen Diagnostics, a division of Ciphergen Biosystems, Inc., (CIPH), announced that it has executed a material transfer agreement with the NCI Clinical Proteomics Reference Laboratory (CPRL) that allows CPRL to evaluate the new ProteinChip System, Series 4000 and ProteinChip arrays and associated bioinformatics suites.

The CPRL was created by the NCI to explore a variety of proteomics platforms, which may have potential use to detect protein patterns indicative of various cancer states.

Under the terms of the agreement, Ciphergen will provide instrumentation, biochip arrays and software that the NCI CPRL will use to study biomarker patterns...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2005-05-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry